{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:08:48Z","timestamp":1790842128760,"version":"4.1.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Institute NIH\/NCI","award":["R01CA251930"],"award-info":[{"award-number":["R01CA251930"]}]},{"name":"NIH\/NCI","award":["R21CA264838"],"award-info":[{"award-number":["R21CA264838"]}]},{"name":"Warley Trust"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Unravel the potential mechanism(s) of the on- and off-target actions of dopamine agonist therapy in both human prolactinoma tumors and neighboring stromal and immune cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design and Methods<\/jats:title>\n                  <jats:p>Five surgically resected prolactinomas (PRLomas) from 3 cabergoline (CBG)-treated patients and 2 treatment-naive patients were analyzed by using single-cell RNA sequencing (scRNA-seq) to compare the cellular composition and transcriptional landscape.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Six major cell populations, namely tumor (88.2%), immune (5.6%), stromal (4.9%), progenitor cells (0.6%), proliferating cells (0.4%), and erythrocytes (0.2%), were observed. Tumor cells from CBG-treated patients expressed lower levels of genes that regulated hormone secretion, such as SCG2, VGF, TIMP1, NNAT, and CALD1, consistent with the inhibitory effects of CBG on hormone processing and secretion. Interestingly, we also observed an increased number of CD8+ T cells in the CBG-treated tissues. These cytotoxic CD8+ T cells expressed killing granule components such as perforin and the granzymes GZMB, GNLY, and KLRD1 as well as the inflammatory cytokine CCL5. Immune cell activation of these CD8+ T cells was further analyzed in a compartment-specific manner, and increased CD25 (IL2R) expression was noted in the CD8+ T cells from the CBG-treated samples. Additionally, and confirming prior reports, we noted a higher stromal cell population in the CBG-treated samples.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our scRNA-seq studies revealed key differences in the transcriptomic features of CBG-treated and CBG-untreated PRLomas in both tumor and microenvironment cellular constituents, and for the first time, describe the previously unknown activation of CD8+ T cells following CBG treatment, which may play a role in the tumoricidal actions of CBG.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvae055","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T18:34:12Z","timestamp":1716489252000},"page":"467-478","source":"Crossref","is-referenced-by-count":7,"title":["Cabergoline targets multiple pathways to inhibit PRL secretion and increases stromal fibrosis"],"prefix":"10.1093","volume":"190","author":[{"given":"Dongyun","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California , Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Hugo","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California , Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin","family":"Bergsneider","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, David Geffen School of Medicine, University of California , Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilene B","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, David Geffen School of Medicine, University of California , Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, David Geffen School of Medicine, University of California , Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karam","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pathology and Lab Medicine, David Geffen School of Medicine, University of California , Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry V","family":"Vinters","sequence":"additional","affiliation":[{"name":"Department of Pathology and Lab Medicine, David Geffen School of Medicine, University of California , Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3865-0810","authenticated-orcid":false,"given":"Anthony P","family":"Heaney","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California , Los Angeles, CA, USA"},{"name":"Department of Neurosurgery, David Geffen School of Medicine, University of California , Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"2","key":"2024062815223535300_lvae055-B1","doi-asserted-by":"crossref","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2024062815223535300_lvae055-B2","first-page":"1012","article-title":"From resistant to aggressive and malignant prolactinomas: a translational approach","volume":"1","author":"Jaffrain-Rea","year":"2014","journal-title":"J Endocr Disord"},{"issue":"14","key":"2024062815223535300_lvae055-B3","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"issue":"1","key":"2024062815223535300_lvae055-B4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000499470","article-title":"Dopamine agonists: from the 1970s to today","volume":"109","author":"Auriemma","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2024062815223535300_lvae055-B5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12902-020-0543-4","article-title":"Predictors of dopamine agonist resistance in prolactinoma patients","volume":"20","author":"Vermeulen","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"2024062815223535300_lvae055-B6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0002-9343(87)90496-7","article-title":"Primary radiotherapy of prolactinomas: eight- to 15-year follow-up","volume":"83","author":"Mehta","year":"1987","journal-title":"Am J Med"},{"issue":"7","key":"2024062815223535300_lvae055-B7","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"issue":"2","key":"2024062815223535300_lvae055-B8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1152\/physiol.00043.2005","article-title":"Dense-core secretory granule biogenesis","volume":"21","author":"Kim","year":"2006","journal-title":"Physiology"},{"key":"2024062815223535300_lvae055-B9","doi-asserted-by":"crossref","first-page":"589786","DOI":"10.3389\/fimmu.2021.589786","article-title":"Connection of BANK1, tolerance, regulatory B CELLS, and apoptosis: perspectives of a reductionist investigation","volume":"12","author":"Le Berre","year":"2021","journal-title":"Front Immunol."},{"key":"2024062815223535300_lvae055-B10","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3389\/fimmu.2018.02285","article-title":"BAFF and BAFF-receptor in B cell selection and survival","volume":"9","author":"Smulski","year":"2018","journal-title":"Front Immunol"},{"key":"2024062815223535300_lvae055-B11","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3389\/fimmu.2019.02458","article-title":"Challenges and opportunities for consistent classification of human B cell and plasma cell populations","volume":"10","author":"Sanz","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"2024062815223535300_lvae055-B12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0014-5793(03)01030-5","article-title":"Expression and regulation of NDRG2 (N-myc downstream regulated gene 2) during the differentiation of dendritic cells","volume":"553","author":"Choi","year":"2003","journal-title":"FEBS Lett"},{"issue":"1","key":"2024062815223535300_lvae055-B13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1189\/jlb.0507300","article-title":"Expression of human NDRG2 by myeloid dendritic cells inhibits down-regulation of activated leukocyte cell adhesion molecule (ALCAM) and contributes to maintenance of T cell stimulatory activity","volume":"83","author":"Choi","year":"2008","journal-title":"J Leukoc Biol"},{"issue":"11","key":"2024062815223535300_lvae055-B14","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.3390\/cells9112374","article-title":"Single-cell transcriptome analysis highlights a role for neutrophils and inflammatory macrophages in the pathogenesis of severe COVID-19","volume":"9","author":"Shaath","year":"2020","journal-title":"Cells"},{"issue":"13","key":"2024062815223535300_lvae055-B15","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1016\/j.celrep.2018.03.010","article-title":"Single-cell deconvolution of fibroblast heterogeneity in mouse pulmonary fibrosis","volume":"22","author":"Xie","year":"2018","journal-title":"Cell Rep"},{"issue":"47","key":"2024062815223535300_lvae055-B16","doi-asserted-by":"crossref","first-page":"13408","DOI":"10.1073\/pnas.1614970113","article-title":"Epithelial cell integrin \u03b21 is required for developmental angiogenesis in the pituitary gland","volume":"113","author":"Scully","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2024062815223535300_lvae055-B17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1530\/EJE-21-1183","article-title":"Single cell RNA sequencing in silent corticotroph tumors confirms impaired POMC processing and provides new insights into their invasive behavior","volume":"187","author":"Zhang","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"42","key":"2024062815223535300_lvae055-B18","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1038\/sj.onc.1207938","article-title":"Identification of novel AP-1 target genes in fibroblasts regulated during cutaneous wound healing","volume":"23","author":"Florin","year":"2004","journal-title":"Oncogene"},{"issue":"11","key":"2024062815223535300_lvae055-B19","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41577-021-00540-z","article-title":"Fibroblasts as immune regulators in infection, inflammation and cancer","volume":"21","author":"Davidson","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2024062815223535300_lvae055-B20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1165\/rcmb.2018-0313OC","article-title":"Defining the activated fibroblast population in lung fibrosis using single-cell sequencing","volume":"61","author":"Peyser","year":"2019","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"10","key":"2024062815223535300_lvae055-B21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/nmeth.4402","article-title":"Reversed graph embedding resolves complex single-cell trajectories","volume":"14","author":"Qiu","year":"2017","journal-title":"Nat Methods"},{"issue":"5","key":"2024062815223535300_lvae055-B22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00415-007-5012-8","article-title":"Dopamine agonists and valvular heart disease in patients with Parkinson's disease: evidence and mystery","volume":"254","author":"Yamamoto","year":"2007","journal-title":"J Neurol"},{"key":"2024062815223535300_lvae055-B23","volume-title":"StatPearls","author":"Choi","year":"2022"},{"issue":"2","key":"2024062815223535300_lvae055-B24","first-page":"246","article-title":"Function and expression differences between ergot and non-ergot dopamine D2 agonists on heart valve interstitial cells","volume":"23","author":"Oana","year":"2014","journal-title":"J Heart Valve Dis"},{"issue":"1","key":"2024062815223535300_lvae055-B25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"2024062815223535300_lvae055-B26","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3171\/2010.11.JNS101369","article-title":"Dopamine agonist-resistant prolactinomas","volume":"114","author":"Oh","year":"2011","journal-title":"J Neurosurg"},{"issue":"4","key":"2024062815223535300_lvae055-B27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/cells8040351","article-title":"p190RhoGAPs, the ARHGAP35- and ARHGAP5-encoded proteins, in health and disease","volume":"8","author":"H\u00e9raud","year":"2019","journal-title":"Cells"},{"issue":"5","key":"2024062815223535300_lvae055-B28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S1534-5807(02)00162-4","article-title":"Modulation of CREB activity by the Rho GTPase regulates cell and organism size during mouse embryonic development","volume":"2","author":"Sordella","year":"2002","journal-title":"Dev Cell"},{"issue":"5","key":"2024062815223535300_lvae055-B29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1534-5807(02)00183-1","article-title":"RhoGAP: the next big thing for small mice?","volume":"2","author":"Birnbaum","year":"2002","journal-title":"Dev Cell"},{"key":"2024062815223535300_lvae055-B30","first-page":"247","volume-title":"The Immune Response","author":"Mak","year":"2006"},{"issue":"1-2","key":"2024062815223535300_lvae055-B31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jneuroim.2004.11.008","article-title":"Prolactin affects both survival and differentiation of T-cell progenitors","volume":"160","author":"Carre\u00f1o","year":"2005","journal-title":"J Neuroimmunol"},{"issue":"7","key":"2024062815223535300_lvae055-B32","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/icb.2008.29","article-title":"Prolactin can modulate CD4+ T-cell response through receptor-mediated alterations in the expression of T-bet","volume":"86","author":"Tomio","year":"2008","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"2024062815223535300_lvae055-B33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12957-021-02272-9","article-title":"Research advances on the immune research and prospect of immunotherapy in pituitary adenomas","volume":"19","author":"Nie","year":"2021","journal-title":"World J Surg Oncol"},{"issue":"9","key":"2024062815223535300_lvae055-B34","doi-asserted-by":"crossref","first-page":"e3207","DOI":"10.1210\/clinem\/dgaa449","article-title":"The immune profile of pituitary adenomas and a novel immune classification for predicting immunotherapy responsiveness","volume":"105","author":"Wang","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024062815223535300_lvae055-B35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11102-022-01211-5","article-title":"The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications","volume":"25","author":"Marques","year":"2022","journal-title":"Pituitary"},{"key":"2024062815223535300_lvae055-B36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fimmu.2018.00073","article-title":"Prolactin and autoimmunity","volume":"9","author":"Borba","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"2024062815223535300_lvae055-B37","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s11102-015-0699-5","article-title":"Prevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenomas","volume":"19","author":"Larouche","year":"2016","journal-title":"Pituitary"},{"issue":"6","key":"2024062815223535300_lvae055-B38","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40618-018-0972-3","article-title":"Autoimmune thyroid diseases are more common in patients with prolactinomas: a retrospective case\u2013control study in an Italian cohort","volume":"42","author":"Pilli","year":"2019","journal-title":"J Endocrinol Invest"},{"issue":"Suppl 2","key":"2024062815223535300_lvae055-B39","first-page":"27","article-title":"Clinical course of autoimmune thyroid diseases in women with prolactinomas: results from a prospective study in a single tertiary centre","volume":"70","author":"Elenkova","year":"2023","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"issue":"1","key":"2024062815223535300_lvae055-B40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13073-021-00881-3","article-title":"IFN-\u03b3 and TNF-\u03b1 drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation","volume":"13","author":"Zhang","year":"2021","journal-title":"Genome Med"},{"issue":"2","key":"2024062815223535300_lvae055-B41","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","article-title":"Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer","volume":"181","author":"Zhang","year":"2020","journal-title":"Cell"},{"issue":"1","key":"2024062815223535300_lvae055-B42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12967-020-02251-w","article-title":"Alternatively activated macrophages; a double-edged sword in allergic asthma","volume":"18","author":"Abdelaziz","year":"2020","journal-title":"J Transl Med"},{"issue":"24","key":"2024062815223535300_lvae055-B43","doi-asserted-by":"crossref","first-page":"9395","DOI":"10.1158\/0008-5472.CAN-09-2050","article-title":"Folate receptor \u03b2 is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory\/regulatory macrophages","volume":"69","author":"Puig-Kr\u00f6ger","year":"2009","journal-title":"Cancer Res."},{"issue":"7","key":"2024062815223535300_lvae055-B44","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/icb.2017.18","article-title":"MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells","volume":"95","author":"Sanyal","year":"2017","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"2024062815223535300_lvae055-B45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2174\/1874306400903010090","article-title":"Pleuropulmonary toxicity of another anti-Parkinson's drug: cabergoline","volume":"3","author":"Belmonte","year":"2009","journal-title":"Open Respir Med J"},{"key":"2024062815223535300_lvae055-B46","first-page":"A2946-A","article-title":"Slowly progressive lung fibrosis (dominant in right upper lobe) after encapsulated pleurisy induced by cabergoline in a patient with Parkinsonism. B40 CASE REPORTS: PLEURAL DISEASES: DIAGNOSTIC DILEMMAS","author":"Eda","year":"2011"},{"issue":"4","key":"2024062815223535300_lvae055-B47","first-page":"187","article-title":"Drug-induced retroperitoneal fibrosis: short aetiopathogenetic note, from the past times of ergot-derivatives large use to currently applied bio-pharmacology","volume":"36","author":"Alberti","year":"2015","journal-title":"G Chir"},{"key":"2024062815223535300_lvae055-B48","volume-title":"Bioscientifica","author":"Jarzynska","year":"2019"},{"issue":"1","key":"2024062815223535300_lvae055-B49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12020-016-1120-5","article-title":"Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia","volume":"55","author":"Vroonen","year":"2017","journal-title":"Endocrine"},{"issue":"2","key":"2024062815223535300_lvae055-B50","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/jpet.102.039883","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"2024062815223535300_lvae055-B51","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0192623310378027","article-title":"Drug-induced valvulopathy: an update","volume":"38","author":"Elangbam","year":"2010","journal-title":"Toxicol Pathol"},{"issue":"4","key":"2024062815223535300_lvae055-B52","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1530\/EJE-09-0989","article-title":"Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline","volume":"162","author":"Lafeber","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"1-2","key":"2024062815223535300_lvae055-B53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0014-2999(01)01605-3","article-title":"Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-ht(1F) receptor","volume":"436","author":"Bhalla","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"2024062815223535300_lvae055-B54","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s13311-018-0615-6","article-title":"Targeted 5-HT(1F) therapies for migraine","volume":"15","author":"Vila-Pueyo","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"3","key":"2024062815223535300_lvae055-B55","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.bjp.0703081","article-title":"No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery","volume":"129","author":"Bouchelet","year":"2000","journal-title":"Br J Pharmacol"},{"issue":"6","key":"2024062815223535300_lvae055-B56","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3390\/genes12060891","article-title":"Molecular cloning and functional characterization of three 5-HT receptor genes (HTR1B, HTR1E, and HTR1F) in chickens","volume":"12","author":"Sun","year":"2021","journal-title":"Genes (Basel)"},{"issue":"6","key":"2024062815223535300_lvae055-B57","doi-asserted-by":"crossref","first-page":"e8746","DOI":"10.15252\/msb.20188746","article-title":"Current best practices in single-cell RNA-seq analysis: a tutorial","volume":"15","author":"Luecken","year":"2019","journal-title":"Mol Syst Biol"},{"issue":"4","key":"2024062815223535300_lvae055-B58","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nbt.2859","article-title":"The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells","volume":"32","author":"Trapnell","year":"2014","journal-title":"Nat Biotechnol"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvae055\/57846177\/lvae055.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/6\/467\/58336520\/lvae055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/6\/467\/58336520\/lvae055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T17:59:09Z","timestamp":1719597549000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/190\/6\/467\/7680516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvae055","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,5,23]]}}}